Granulomatous-lymphocytic interstitial lung disease: an international research prioritisation.

The first ever research prioritisation exercise in GLILD: this survey identified areas of interest in the diagnosis, treatment and management of GLILD, which can be used as a roadmap for future research https://bit.ly/3nVuzti.
Competing Interests: Provenance: Submitted article, peer reviewed.Conflict of interest: J.R. Hurst reports grants, personal fees and nonfinancial support from pharmaceutical companies that make medicines to treat respiratory and immunological diseases outside the submitted work. Conflict of interest: S.M. Abbas has nothing to disclose. Conflict of interest: H.M. Bintalib has nothing to disclose. Conflict of interest: T.M. Alfaro has nothing to disclose. Conflict of interest: U. Baumann has nothing to disclose. Conflict of interest: S.O. Burns reports personal fees from CSL Behring, Baxalta US Inc., Biotest, the European Union, the National Institute of Health Research, UCLH and GOSH/Institute of Child Health Biomedical Research Centers, and CSL Behring, outside the submitted work. Conflict of interest: A. Condliffe has nothing to disclose. Conflict of interest: J.R. Davidsen has nothing to disclose. Conflict of interest: B. Fevang has nothing to disclose. Conflict of interest: A.R. Gennery has nothing to disclose. Conflict of interest: F. Haerynck has nothing to disclose. Conflict of interest: J. Jacob reports personal fees from Boehringer Ingelheim, Roche and GlaxoSmithKline, outside the submitted work. Conflict of interest: S. Jolles has nothing to disclose. Conflict of interest: O. Lamers has nothing to disclose. Conflict of interest: A. Bergeron reports grants from SOS Oxygene, personal fees from Takeda, and personal fees from AstraZeneca, Pfizer, MSD, Gilead and Enanta, outside the submitted work. Conflict of interest: M. Malphettes has nothing to disclose. Conflict of interest: V. Meignin has nothing to disclose. Conflict of interest: C. Milito has nothing to disclose. Conflict of interest: T. Milota has nothing to disclose. Conflict of interest: M. Pergent has nothing to disclose. Conflict of interest: A. Prasse reports personal fees from Boehringer Ingelheim, Roche, Novartis, Chiesi, Pliant and AstraZeneca outside the submitted work. Conflict of interest: I. Quinti has nothing to disclose. Conflict of interest: E. Renzoni reports grants from Boehringer Ingelheim, and lecture fees from Boehringer Ingelheim and Roche, outside the submitted work. Conflict of interest: A. Sediva has nothing to disclose. Conflict of interest: D. Stolz reports grants from AstraZeneca AG, Curetis AG and Boston Scientific, and payment for lectures and/or advisory boards from AstraZeneca AG, Novartis AG, GSK AG, Roche AG, Zambon, Pfizer, Schwabe Pharma AG, Vifor AG, Chiesi AG and MSD, outside the submitted work. Conflict of interest: B. Smits has nothing to disclose. Conflict of interest: F. Strauss has nothing to disclose. Conflict of interest: A.A.J.M. van de Ven has nothing to disclose. Conflict of interest: J. van Montfrans reports having participated in an advisory board for Takeda during the conduct of the study. Conflict of interest: K. Warnatz reports grants from Bristol Myers Squibb outside the submitted work.
(Copyright ©The authors 2021.)